Authors
Latest:
Dr. Cho on the Updated Efficacy of Repotrectinib in TKI-Naïve ROS1+ NSCLCByoung Chul Cho, MD, PhD, discusses the updated efficacy reported with repotrectinib in TKI-naïve patients with ROS1-positive non–small cell lung cancer.
Latest:
A Primer on Rising Medical Cannabis Use in OncologyUnsurprisingly, the use of cannabis in patients with cancer appears to be increasing as more and more states are adopting cannabis legislation, both for medical and adult use.
Latest:
Navigating the Complexities of Cancer CareThe Allegheny Health Network's comprehensive cancer navigation program supports all cancer patients from diagnosis to treatment and beyond.
Latest:
Dr Johnson on Trastuzumab Plus Paclitaxel in HER2+ Breast CancerKai Conrad Cecil Johnson, MD, discusses key invasive disease-free survival findings from the final 10-year analysis of the phase 2 APT trial and HER2DX exploratory analyses in patients with HER2-positive breast cancer.
Latest:
Insights from IMS 2024 on Counseling Patients with Multiple Myeloma about CAR T-cell Therapy and Connecting to Referral CentersPanelists discuss how community providers can implement strategies and utilize resources to effectively connect patients to referral centers for chimeric antigen receptor T-cell therapy, while addressing how to initiate conversations about the therapy and counsel patients regarding potential adverse events.
Latest:
Dr Feun on the Evolving Treatment Paradigm in HCCLynn G. Feun, MD, discusses the evolution of treatment approaches in hepatoceullar carcinoma, the influence of immunotherapies on patient outcomes in this armamentarium, and ongoing avenues of investigation within in the field of HCC management.
Latest:
Dr Kelly on Ongoing Trials in Patients With GISTCiara Kelly, MBBCh, BAO, discusses ongoing trials to further enhance the treatment of patients with gastrointestinal stromal tumor.
Latest:
Dr. Hassan on the Mechanism of Action of Talazoparib in TNBCSaima Hassan, MD, PhD, FRCSC, discusses the mechanism of action of talazoparib in triple-negative breast cancer.
Latest:
Dr Lowentritt on the Exploration of Active Surveillance in Prostate CancerBenjamin H. Lowentritt, MD, FACS, discusses the exploration of active surveillance in patients with prostate cancer.
Latest:
WCLC Updates in Small Cell Lung CancerPanelists provide first impressions on recent clinical trials in the treatment of small cell lung cancer and comment on the safety and efficacy of study treatments.
Latest:
Dr Pachynski on the Ongoing Investigation of ARX517 in Advanced Solid TumorsRussell Pachynski, MD, discusses the ongoing investigation of ARX517 in patients with advanced solid tumors in the phase 1/2 APEX-01 trial.
Latest:
Dr Morelli on the Ongoing Investigation of A2B530 in Advanced or Metastatic Solid TumorsMaria Pia Morelli, MD, PhD, discusses the ongoing investigation of A2B530, a Tmod™ CAR T-cell therapy, in advanced or metastatic solid tumors and highlights forward-facing research with the agent.
Latest:
Dr Patel on the Impact of Donor-Engrafted Clonal Hematopoiesis on Outcomes With Auto-/Allo-HSCTShyam A. Patel, MD, PhD, discusses the impact of donor-engrafted clonal hematopoiesis on the risk of disease relapse and survival outcomes with allo- and auto-HSCT.
Latest:
Dr Eroglu on Addressing Unmet Needs in Mutant MelanomaZeynep Eroglu, MD, discusses a phase 1/2 trial that evaluated ceritinib alone and in combination with trametinib in patients with mutant melanoma.
Latest:
Unmet Needs in the Treatment of HR+/HER2- Breast CancerClosing their discussion, the panel shares some remaining unmet needs in the treatment and management of patients with HR+/HER- breast cancer.
Latest:
Dr Mina on the Evolution of T-DM1 and T-DXd in HER2+ Breast CancerLida A. Mina, MD, discusses the evolution of the antibody-drug conjugates fam-trastuzumab deruxtecan-nxki and ado-trastuzumab emtansine in HER2-positive breast cancer.
Latest:
Dr. Sperling on Future Research With CAR T-Cell Therapy in Multiple MyelomaAdam Sperling, MD, PhD, discusses future research with CAR T-cell therapy in multiple myeloma.
Latest:
Cracking the Cancer Code Requires Both Quiet and ChaosMatthew L. Meyerson, MD, PhD, is constantly curious, both about the world and the people around him and as one of the top cancer researchers on the planet, he has a talent for elevating younger scientists, turning obstacles into discoveries, and sensing future research opportunities.
Latest:
Dr. Gorlick on the Challenges of Identifying Immunotherapeutic Targets in OsteosarcomasRichard Gorlick, MD, discusses the challenges of identifying immunotherapeutic targets in osteosarcomas.
Latest:
Dr. Indini on the Rationale for the PULSAR Trial in Classic Kaposi SarcomaAlice Indini, MD, discusses the rationale for the phase 2 PULSAR trial in classic Kaposi sarcoma.
Latest:
Dr. Abu-Zeinah on the Efficacy of Interferon-Alpha in Polycythemia VeraGhaith Abu-Zeinah, MD, discusses the efficacy of interferon-alpha in polycythemia vera.
Latest:
City of Hope’s Loretta Erhunmwunsee, MD, Named Cancer Moonshot Scholar by Biden Cancer MoonshotThe program supports early-career researchers and helps build a cancer research workforce that better represents the diversity of America.
Latest:
Tusamitamab Ravtansine Plus Ramucirumab as 2L Therapy or Beyond in Patients With Metastatic NSq NSCLC and High CEACAM5 Expression (CARMEN-LC04)Grace Dy, MD, presents data from the CARMEN-LC04 study evaluating safety and anti-tumor activity of tusamitamab ravtansine combined with ramucirumab in high CEACAM5-expressing non-squamous cell (NSQ) NSCLC tumors.
Latest:
Memorial Sloan Kettering Cancer Center Launches MSKCC India to Expand Access to World-Renowned Oncologists, Cancer Care, Research, and EducationMemorial Sloan Kettering Cancer Center, the world’s oldest and largest private cancer center, has launched MSKCC India to provide cancer patients in India with access to the institution’s world-renowned oncologists, research, clinical trials, and education.
Latest:
New Cancer Study Results Confirm Lasting Effects on 9/11 First RespondersResearch investigating the physical and mental health consequences of being at the World Trade Center site during and after the terrorist attacks has been instrumental in obtaining health care coverage for thousands of individuals.
Latest:
Dr. Lees on the Utility of Genetic Testing in Ovarian CancerBrittany F. Lees, MD, discusses the utility of genetic and genomic testing in ovarian cancer.
Latest:
Dr Saliby on the Correlation Between Intermediate End Points and OS in RCCRenee Saliby, MD, MSc, discusses the investigation of the correlation between intermediate end points and OS in metastatic renal cell carcinoma.
Latest:
Dr. Binder on the Use of Immune Checkpoint Inhibitors in Endometrial Cancer TreatmentPratibha Binder, MD, discusses how the introduction of novel immune checkpoint inhibitors into frontline treatment strategies could ameliorate unmet needs in endometrial cancer.
Latest:
Schmid Summarizes Updates in HER2-Positive Breast Cancer ManagementDr Schmid discusses considerations for applying recent data updates in HER2-positive breast cancer management to clinical practice.
Latest:
Dr Torres on Treatment With ADCs in Breast CancerMylin A. Torres, MD, discusses using antibody-drug conjugates (ADCs) to treat patients with breast cancer.
.jpg?fit=crop&auto=format)
